Charles Schwab Investment Management Inc Rallybio Corp Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$4.31 - $8.89 $96,397 - $198,833	22,366 Added 40.92%	77,018 $435,000
Q1 2023 May 11, 2023	BUY	$4.37 - $8.75 $35,724 - $71,531	8,175 Added 17.59%	54,652 $312,000
Q4 2022 Feb 13, 2023	BUY	$4.67 - $14.86 $29,094 - $92,577	6,230 Added 15.48%	46,477 $305,000
Q2 2022 Aug 15, 2022	SELL	$6.26 - $13.65 $33,390 - $72,809	-5,334 Reduced 11.7%	40,247 $304,000
Q1 2022 May 13, 2022	BUY	$6.91 - $15.04 $203,879 - $443,755	29,505 Added 183.53%	45,581 $319,000
Q4 2021 Feb 11, 2022	BUY	$9.3 - $19.91 $15,140 - $32,413	1,628 Added 11.27%	16,076 $154,000
Q3 2021 Nov 16, 2021	BUY	$10.83 - $23.4 $156,471 - $338,083	14,448 New	14,448 $254,000

31.7M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $27.6M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.